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A Novel CDK9-Associated C-Type Cyclin Interacts
Directly with HIV-1 Tat and Mediates Its
High-Affinity, Loop-Specific Binding to TAR RNA
(Tiley et al., 1992; Ghosh et al., 1993). Second, the full-
length Tat-1 protein, butnot a mutant Tat protein lacking
the transactivation domain, is able to target a heterolo-
gous protein to TAR RNA in vivo (Luo et al., 1993). Third,
Tat transactivation through TAR is blocked by amino
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acid insertions that separate the activation domain fromLa Jolla, California 92037-1099
the ARM (Luo and Peterlin, 1993), and the isolated ARM³Graduate Program in Biomedical Sciences
does not function as a dominant negative inhibitor ofUniversity of California, San Diego
the wild-type Tat protein (Madore and Cullen, 1993).La Jolla, California 92093
In addition, residues in the core of the transactivation
domain enhance the affinity and specificity of the
Tat:TAR interaction in vitro (Churcher et al., 1993). Taken
Summary
together, these studies suggest that the transactivation
domain is required, directly or indirectly, for efficientThe HIV-1 Tat protein regulates transcription elonga-
binding of Tat to TAR RNA in vivo.tion through binding to the viral TAR RNA stem-loop
In vitro, Tat binds to the bulge region of TAR RNA but
structure. We have isolated a novel 87 kDa cyclin
does not recognize sequences in the loop of the RNA
C±related protein (cyclin T) that interacts specifically
hairpin that are essential for transactivation. Moreover,
with the transactivation domain of Tat. Cyclin T is a exogenous Tat cannot overcome the specific inhibition
partner for CDK9, an RNAPII transcription elongation to Tat transactivation that is observed when cells or cell
factor. Remarkably, the interaction of Tat with cyclin extracts are treated with synthetic TAR (decoy) RNAs.
T strongly enhances the affinity and specificity of Consequently, it has been suggested that Tat must first
the Tat:TAR RNA interaction, and confers a require- interact with a host cell factor in order to recognize TAR
ment for sequences in the loop of TAR that are not RNA with high affinity and in a sequence-appropriate
recognized by Tat alone. Moreover, overexpression manner (reviewed by Cullen 1993; Jones and Peterlin,
of human cyclin T rescues Tat activity in nonpermis- 1994). Additional evidence in support of a cofactor for
sive rodent cells. We propose that Tat directs cyclin Tat comes fromthe observation that murine and Chinese
T±CDK9 to RNAPII through cooperative binding to TAR hamster ovary (CHO) cell lines do not support efficient
RNA. Tat activation through TAR RNA, and studies with chi-
meric Tat proteins have attributed the defect in rodent
Introduction cells to a problem of TAR RNA recognition. Complemen-
tation studies using human:CHO hybrid cell clones re-
The human immunodeficiency virus (HIV) encodes a nu- vealed that a factor encoded on human chromosome
clear transcriptional activator, Tat, which acts to en- 12 (Chr. 12) enhances Tat activity 5- to 10-fold in rodent
hance the processivity of RNA polymerase II (RNAPII) cells and confers a requirement for sequences in the
complexes that would otherwise terminate transcrip- loop of TAR RNA (Hart et al., 1993; Alonso et al., 1994).
tion prematurely at random locations downstream of the By contrast with the ARM, the N-terminal half of Tat
viral RNA start site. The mechanism of Tat transacti- (aa 1±48) functions autonomously as a transcriptional
vation is unique in that the cis-acting transactivation activation domain in the context of a chimeric DNA- or
response element (TAR) is a stable RNA stem-loop RNA-binding protein and can act on its own to inhibit
structure that forms at the 59 end of nascent viral tran- (or ªsquelchº) the activity of the wild-type Tat protein
scripts. Transcriptional activation by Tat through TAR (reviewed by Cullen, 1993; Jones and Peterlin, 1994). Tat
requires proper folding of the RNA as well as specific acts through TAR to control an early step in transcription
bases in the bulge and apical loop of the TAR RNA elongation that is sensitive to inhibition by protein kinase
hairpin structure (for review, see Cullen, 1993; Jones inhibitors and requires the carboxyl-terminal domain
(CTD) of the large subunit of RNA polymerase II (re-and Peterlin, 1994).
viewed by Jones, 1997). The transactivation domain ofThe interaction of Tat with TAR RNA is mediated
Tat interacts strongly with a nuclear Tat-associated ki-through an arginine-rich motif (ARM) that is characteris-
nase, called TAK (Herrmann and Rice, 1993; 1995),tic of a family of sequence-specific RNA-binding pro-
which was recently shown to be identical to the kinaseteins (reviewed by Gait and Karn, 1993). However, sev-
subunit of P-TEFb (Mancebo et al., 1997; Zhu et al.,eral lines of evidence suggest that the ARM of Tat is
1997), a positive-acting transcription elongation factornot an independent domain. First, the transactivation
complex that is required for elongation at many genesdomain of Tat cannot be substituted by the activation
(Marshall and Price, 1992, 1995). Purified TAK/P-TEFbdomains of other transcription factors, such as the her-
can hyperphosphorylate the RNAPII CTD (Marshall et al.,pesvirus VP16 protein, even though the VP16 activation
1996; Yang et al. 1996). Biochemical analysis of purifieddomain is capable of activating transcription when re-
TAK/P-TEFb identified the 42 kDa catalytic subunit as acruited to RNA through a different RNA-binding domain
CDC2-related kinase, PITALRE (hereafter called CDK9),
and CDK9 inhibitors as well as a dominant negative
CDK9 mutant were found to block Tat transactivation§To whom correspondence should be addressed.
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in vivo and in vitro, indicating that CDK9 kinase activity
is critical for Tat activity (Mancebo et al., 1997; Yang et
al. 1997; Zhu et al., 1997). Taken together, these studies
provide strong evidence that the CDK9-containing TAK/
P-TEFb complex is an important host cell transcriptional
coactivator for Tat.
We have recently found that the addition of Tat to
nuclear extracts induces the binding of CDK9-con-
taining TAK/P-TEFb complexes to TAR RNA (M. E. G.,
P. W., and K. A. J., unpublished data). Moreover, we
noted that the nuclear Tat-TAK/P-TEFb complexes did
not associate with loop mutant TAR RNA, indicating that
the interaction of Tat with TAK/P-TEFb might alter its
RNA-binding specificity. In this paper, we report the
cloning of a novel 87 kDa cyclin C±related protein,desig-
nated cyclin T, which is a constituent of the Tat-associ-
ated TAK/P-TEFb complex in HeLa nuclear extracts.
Interestingly, we find that purified recombinant cyclin T
interacts specifically with Tat and dramatically enhances
its affinity for TAR RNA. Most importantly, the binding
of recombinant cyclin T±Tat complexes to TAR RNA was
found to require sequences in the loop of TAR RNA
that are not recognized by free Tat alone. These results
suggest that Tat can recruit cyclin T±CDK9 complexes
to RNAPII through cooperative binding to nascent TAR
RNA. Based on these findings, we propose that cyclin
T is the TAR RNA-binding cofactor for Tat.
Results
Identification of a Nuclear 87 kDa Protein
Associated with HIV-1 Tat in the
TAK/P-TEFb Complex
To further characterize the proteins in the TAK/P-TEFb
complex that interact with the transactivation domain of Figure 1. Identification of an 87 kDa HeLa Nuclear Protein (p87) that
Associates Specifically with the Transactivation Domain of HIV-1Tat, GST-Tat-1 (aa 1±48)±coupled beads were incubated
Tatwith a crude HeLa nuclear extract, and the nuclear pro-
(A) HeLa nuclear proteins associated with GST-Tat-1 (aa 1±48)-cou-teins associated with the transactivation domain of
pled beads were isolated and analyzed for kinase activity (left panel)HIV-1 Tat were analyzed by SDS-PAGE and silver-stain-
or by SDS-PAGE (right panel). Approximately 15 mg of each GST-
ing. As shown in Figure 1A (right panel), an 87 kDa Tat protein was incubated with 1 mg of HeLa nuclear extract; one-
protein (p87) was found to bind avidly to the wild-type third of the reaction was analyzed for TAK activity (left panel), and
HIV-1 Tat protein and not to mutant GST-Tat (aa 1±48) the remainder was examined by silver-staining (right panel). Wild-
type (wt) and mutant GST-Tat-1 (aa 1±48) proteins are indicatedproteins (P18IS, C22G, K41A) containing substitutions
above each lane. A 63 kDa protein seen exclusively in the wild-that inactivate Tat transactivation in vivo (Herrmann and
type GST-Tat fraction is a contaminant originating from the TatRice, 1993, 1995). Both p87 and the 42 kDa CDK9 sub-
preparation.
unit of the TAK/P-TEFb complex were phosphorylated (B) Top panel: analysis of wild-type GST-Tat-1 and transdominant
when the GST-Tat-1 (aa 1±48) beads were incubated GST-Tat-1 (aa 1±48) proteins by run-off transcription experiments.
Transdominant GST-Tat proteins, indicated above each lane, werewith [g-32P]ATP and analyzed for TAK activity (Figure 1A,
preincubated with HeLa nuclear extract prior to transcription.left panel). As expected, CDK9 was also detected only
Arrows indicate the location of run-off transcripts from the wild-typein association with the wild-type Tat protein. Interest-
(wt) pHIV-2/CAT or the control pHIV-2DTAR/CAT (DTAR) template.
ingly, the 87 kDa protein was recovered in apparent Bottom panel, left: analysis of the ability of nuclear extract or phos-
stoichiometric excess to the CDK9 protein (Figure 1A, phocellulose column fractions to restore transactivation to reactions
right panel), suggesting that Tat might interact most that were inhibited by incubation with GST-Tat-1 (aa 1±48). Reac-
tions were supplemented with either HeLa nuclear extract (IN, 60tightly with the p87 subunit of the TAK/P-TEFb complex.
mg; lanes 3 and 4), P0.1 MKCl (FT; lanes 5 and 6), P0.3 MKCl (lanesThe GST-Tat-1 (aa 1±48) protein used in these experi-
7 and 8), or P0.5 MKCl (lanes 9 and 10) phosphocellulose columnments contained a functional transactivation domain,
fractions. Bottom panel, right: Tat-associated kinase activity in the
as demonstrated by its ability to block (ªsquelchº) tran- nuclear extract (IN) or column fractions.
scriptional activation by wild-type Tat-1 in vitro when
incubated with nuclear transcription extracts at levels
1.5- to 15-fold higher than the wild-type Tat-1 protein that contains an intact transactivation domain but lacks
the ARM. The GST-Tat-1 (aa 1±48) and GST-Tat-2 (aa(Figure 1B). Comparable inhibition of Tat transactivation
was observed with a mutant GST-Tat-2 (aa 1±84) protein 1±84) proteins did not block basal transcription in the
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absence of Tat, nor did they affect transcription from
HIV templates that lack TAR (DTAR). The ability of these
truncated Tat proteins to inhibit Tat transactivation in
vitro was destroyed by mutations affecting key residues
within the transactivation domain (Tat-1 K41A, Tat-1
C22G, Tat-1 P18IS, Tat-2 D8±47) (Figure 1B; other data
not shown). Inhibition of Tat transactivation by Tat-1
(aa 1±48) could not be overcome by the addition of
exogeneous wild-type Tat protein, but was restored by
nuclear extract (Figure 1B, compare lanes 1 and 2 with
lanes 3 and 4). Fractionation of the HeLa nuclear extract
by phosphocellulose column chromatography revealed
that the Tat-associated p87 and CDK9 proteins eluted
principally in the P0.5MKCl fraction, as determined by
SDS-PAGE and silver-staining for the p87 protein (data
not shown), and by the in vitro kinase assay (Figure
1B, lower right panel). The P0.5MKCl fraction was as
effective as nuclear extract in its ability to restore
Tat-activated transcription to reactions that had been
inhibited by incubation with GST-Tat-1 (aa 1±48) (Figure
1B, lanes 9 and 10), whereas the other column fractions
were inactive. Collectively, these data suggest that p87
is a component of the TAK/P-TEFb complex that binds
tightly to the transactivation domain of HIV-1 Tat.
Molecular Cloning of p87 (Cyclin T)
To better characterize the 87 kDaprotein, approximately
110 pmol of p87 was isolated from 40 mg of crude HeLa
nuclear extract using a scaled-up version of the GST-
Tat-1 (aa 1±48) affinity selection protocol used in Figure
1A (see Experimental Procedures). The p87 protein was
excised from a preparative SDS-PAGE and subjected
to tryptic digestion, and nine different tryptic peptide
fragments were purified by HPLC and subjected to mi-
crosequence analysis. The derived amino acid se-
quence established that p87 was a novel protein, and a
search of the GenBank database revealed an expressed
sequence tag clone (EST yd48c03; I.M.A.G.E. ID111460)
that encoded several of the p87-derived peptides. A
RACE RCR protocol was used to extend the cDNA clone
to the 39 end. A human Jurkat (T cell) cDNA library was
then screened with radiolabeled probes derived from
Figure 2. Analysis of the Sequence and Predicted Domain Structure
the EST cDNA and 39RACE PCR products, and a 7.2 kB of the Human Cyclin T (p87) Protein
cDNA clone encompassing the entire (726 amino acid) (A) Amino acid sequence of human cyclin T encoded by the 2.3 kb
open reading frame (ORF), as well as 59- and 39-untrans- cDNA.
lated leader sequences, was isolated and sequenced. (B) Predicted domain structure of human cyclin T. The locations of
nine peptides (P1±9) derived from microsequencing of purified HeLaInspection of the amino acid sequence encoded by the
p87 are indicated below the diagram.cDNA (Figure 2A) revealed the presence of all nine pep-
(C) Northern blot analysis of cyclin T mRNA in various human tissuestides obtained from the native p87 protein (P1±P9; Fig-
(Clontech), using a probe corresponding to the cyclin homology
ure 2B). In vitro translation of the cDNA clone confirmed domain (aa 1±176).
that the intact ORF encodes a protein of 87 kDa (data
not shown), indicating that the open reading frame is
complete. Pch1(1), which was isolated through its ability to interact
with CDC2 (Furnari et al., 1997). In addition to theDatabase searches with the predicted protein se-
quence (hereafter called cyclin T, for Tat) identified an N-terminal cyclin domain, the cyclin T protein contains
a putative coiled-coil motif (aa 379±430), a His-rich motifamino-terminal cyclin box motif that is closely related
(39% identity within the most conserved 25 aa region (aa 506±530) and a carboxy-terminal PEST sequence
(aa 709±726; Figure 2B). C-terminal PEST sequencesof the cyclin box) to human cyclin C. A longer 250 aa
region encompassing the entire duplicated cyclin fold are commonly found in G1 cyclins and serve to regulate
protein turnover by the cellular ubiquitination and prote-is highly conserved amongst C-type cyclins from various
organisms (alignment not shown). Cyclin T is most olysis pathways (Rechsteiner and Rogers, 1996). Cyclin
T is encoded by a single gene, and its genomic locationclosely related to the essential S. pombe C-type cyclin,
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has been mapped from sequence-tagged sites (STS
G25423; G28091) to a position located 295.9 cR (cen-
tirays; 1 cR 5 270 kb) from the top of human chromo-
some 12.
Northern blot analysis with a probe derived from the
region of the cyclin box (aa 1±176) revealed that the
major cyclin T transcript (8 kb) is widely expressed in
human tissues (Figure 2C). A larger transcript (z9.5 kb)
was also detected in peripheral blood lymphocytes
(PBLs), and relatively high levels of a shorter transcript
(3.0 kb) were detected exclusively in the testis. These
same transcripts were also detected with a radiolabeled
probe derived from the C-terminal region of the cyclin
T gene, and, in addition, the C-terminal probe detected
an abundant 3.5 kb transcript in the ovary, which did
not hybridize to a probe from the cyclin box (data not
shown). These results indicate that cyclin T mRNA is
expressed widely in adult human tissues and may be
spliced differentially in PBLs as well as in cells derived
from the human germ line.
Cyclin T Interacts with CDK9 in Nuclear
Extracts and Is Required for RNAPII
Transcription Elongation In Vitro
To confirm that the cyclin T cDNA encodes the 87 kDa
Tat-associated protein that we originally identified in
HeLa nuclear extracts, a region near the carboxy-termi-
nus of cyclin T was expressed in bacteria and used to
generate rabbit polyclonal antiserum. Both the native
87 kDa cyclin T protein and CDK9 were detected by
immunoprecipitation using the anti-cyclin T antibodies,
and the same proteins were also detected with anti-
CDK9 (PITALRE) antiserum (Figure 3A). The identity of
the 87 kDa and 42 kDa proteins as cyclin T and CDK9,
respectively, was established by Western blot analysis
of the immunoprecipitated reactions (data not shown).
Neither cyclin T nor CDK9 were detected in control im-
munoprecipitation reactions with preimmune serum (Fig-
ure 3A). Western blot analysis was used to confirm the
presence of native cyclin T and CDK9 proteins in TAK/
P-TEFb fractions derived by GST-Tat affinity selection
from HeLa nuclear extract (Figure 3B). We conclude that
cyclin T, like CDK9, associates specifically with the wild-
type Tat-1 and Tat-2 proteins and not with mutant Tat
proteins altered within the transactivation domain.Figure 3. Cyclin T Is a Partner for CDK9 (PITALRE) and Is Required
for Transcription Elongation In Vitro Previous studieshave shown that P-TEFbis critical for
(A) Cyclin T associates with CDK9 in nuclear extracts. Immunopre- DRB-sensitive RNAPII transcription elongation at many
cipitation reactions with HeLa nuclear extract were carried out using promoters (Marshall and Price, 1995; Marshall et al.,
antisera specific either to cyclin T or CDK9 (PITALRE), or with preim- 1996; Zhu et al., 1997), and immunodepletion of CDK9
mune serum. Proteins were visualized by staining with silver (left
from HeLa nuclear extracts has been shown to inhibitpanel) or by incubation of the beads with [32P]ATP to analyze phos-
RNAPII elongation as well as Tat transactivation (Mancebophorylated proteins (right panel). The identification of cyclin T and
et al., 1997; Zhu et al., 1997). To test the role of theCDK9 was confirmed by Western blot (data not shown).
(B) Analysis of the binding of nuclear cyclin T and CDK9 to wild- cyclin T±CDK9 complex in transcription, HeLa nuclear
type and activation domain mutant HIV-1 and HIV-2 Tat proteins. extracts were depleted of endogeneous cyclin T by re-
HeLa nuclear extract was incubated with various GST-Tat proteins peated incubation with anti-cyclin T antibody-coupled
coupled to beads as described in Figure 1A, and cyclin T and CDK9
proteins were examined by Western blot.
(C) Cyclin T is required for HIV-1 transcription elongation and Tat
transactivation in vitro. RNA initiation from the HIV-2 and adenovirus
major late promoter was analyzed by primer extension, and RNA (D) Analysis of the ability of recombinant cyclin T to bind directly to
elongation and Tat transactivation was measured using a run-off Tat. Different HIV-1 and HIV-2 GST-Tat proteins were coupled to
transcription assay. HeLa nuclear extracts were depleted with con- beads and incubated with GST-cleaved cyclin T, as indicated above
trol (GST-specific) antiserum (lanes 3 and 4), or with antiserum spe- each lane. The binding of cyclin T to the different GST-Tat proteins
cific to cyclin T (lanes 5±8), as indicated above each lane. was visualized by Western blot.
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beads. Western blot analysis indicated that this proce- the affinity of free Tat for the TAR-2 loop mutant RNA
is significantly higher than that observed for wild-typedure resulted in the loss of approximately 80% of the
endogeneous HeLa cyclin T protein as well as at least TAR-1 RNA in vitro (M. E. G., P. W., and K. A. J, unpub-
lished data). Therefore, the interaction of Tat with a cellu-50% of the endogeneous CDK9 (data not shown). Analy-
sis of the transcriptional activity of the cyclin T±depleted lar RNA-binding cofactor is predicted to enhance selec-
tively the affinity of Tat for wild-type TAR-1 RNA, as wellextracts revealed that the loss of cyclin T had only a
modest effect on transcription initiation from the HIV-1 as block the residual nonspecific binding of Tat to the
bulge region on TAR-1 and TAR-2 loop mutant RNAs.promoter and no effect on initiation from other promot-
ers (HIV-2, alpha-globin, and AdMLP) as determined by To determine whether the interaction of Tat with cyclin
T alters its TAR RNA recognition properties, gel mobilityprimer extension (Figure 3C; other data not shown). By
contrast, immunodepletion of cyclin T caused a dramatic shift experiments were carried out with recombinant Tat
and cyclin T proteins and wild-type and loop mutantreduction in the synthesis of longer run-off transcripts
from the wild-type and TAR-deleted HIV promoter tem- HIV-1 and HIV-2 TAR RNAs. The full-length HIV-1 Tat
bound weakly to wild-type TAR-1 RNA (Figure 4A, laneplates, and also greatly reduced TAR-dependent trans-
activation by Tat (Figure 3C). Transcription elongation 5), and a four-base substitution of residues in the loop
of TAR-1 reduced the binding of Tat by approximatelywas unaffected in extracts treated with control (GST)
antiserum. From these results, we conclude that cyclin 3-fold (Figure 4A, lane 6). Interestingly, the binding of
HIV-1 Tat to TAR-1 RNA was dramatically enhanced inT is required, directly or indirectly, for elongation of
transcription by RNAPII. the presence of cyclin T (compare lanes 5 and 7), and
the cyclin T±Tat complex did not bind to loop mutant
TAR-1 RNA (lane 8). Cyclin T had no significant effectRecombinant Cyclin T Interacts Directly with the
on the binding of mutant Tat proteins that lack a func-Transcriptional Activation Domain of Tat
tional transactivation domain (C22G, P18IS; lanes 9±16).Because p87 was most prominent among the nuclear
Cyclin T also strongly enhanced the binding of Tat to aproteins that bound to the Tat transactivation domain
minimal TAR RNA element (117 to 143) and mutationsin extract (see Figure 1A), it was important to determine
in either the loop or bulge of the TAR RNA destroyedwhether the recombinant p87 protein could interact di-
the interaction (Figure 4A, compare lane 23 with lanesrectly with Tat. Recombinant cyclin T protein was ex-
24 and 25). We conclude that the binding of Tat-1 topressed in bacteria and purified as a GST±cyclin T fusion
cyclin T strongly enhances its affinity for TAR RNA, andprotein, and the GST domain was removed by cleavage
that the formation the cyclin T±Tat:TAR complex re-with thrombin. Purified cyclin T was then incubated with
quires both the integrity of the Tat transactivation do-wild-type or mutant GST-Tat-coupled beads and the
main as well as sequences in the loop and bulge of theaffinity column eluates were analyzed for binding of
TAR RNA hairpin. Moreover, purified cyclin T displayedcyclin T by Western blotting. As shown in Figure 3D,
no affinity for TAR RNA in the absence of Tat (Figurecyclin T bound to wild-type GST-Tat-1 and GST-Tat-2
4A, lanes 3 and 4), indicating that the ability of cyclin Tproteins, as well as to truncated Tat proteinsthat contain
to associate with TAR depends entirely upon its abilityan intact transactivation domain. By contrast, cyclin T
to bind cooperatively with Tat to the RNA.did not associate with either GST or mutant Tat-1 (K41A)
Tat binds with intrinsically higher affinity to TAR-2or Tat-2 (Tat-2 D8±47) proteins. Moreover, we also found
RNA than TAR-1 RNA and recognizes two or possiblythat GST-cleaved Tat-2 protein bound in an activation
three sites on the duplicated TAR-2 hairpin structure.domain±dependent manner to GST±cyclin T±coupled
Addition of cyclin T to the wild-type Tat-2 protein yieldedbeads (data not shown), and we conclude that cyclin T
a new complex containing both the cyclin and Tat-2,binds directly to the transactivation domains of theHIV-1
and the cyclin T±Tat-2 complex did not bind to a doubleand HIV-2 Tat proteins in vitro.
loop mutant TAR-2 RNA (Figure 4B, compare lanes 7
and 8). Cyclin T did not bind TAR-2 RNA in the absence
The Interaction of Cyclin T with Tat Dramatically of Tat and did not affect the binding of a mutant Tat-2
Enhances Its Affinity for TAR RNA and Alters protein lacking the transactivation domain (Tat-2 D8±47).
the Specificity of the Tat:TAR Interaction Because Tat has a higher affinity for TAR-2 RNA than
If the cyclin T subunit of the TAK/P-TEFb complex is for TAR-1 RNA, the extent of cooperativity observed
indeed the direct target for Tat in the cell, we reasoned upon addition of cyclin T was less dramatic than that
that the interaction between Tat and cyclin T might have observed for Tat-1 on TAR-1 RNA; however, the binding
a dramatic effect on binding to TAR RNA. Binding of of cyclin T and Tat-2 iscooperative at limiting concentra-
Tat to TAR RNA in vitro does not correlate well with the tions of Tat-2 (data not shown), and cyclin T can be
sequence requirements for TAR in Tat transactivation, shown to enhance the binding of Tat-2 to TAR in RNase
and in particular, Tat binding is only modestly affected footprint protection experiments, which are more sensi-
by mutations in the loop of the RNA that play a critical tive to the formation of stable complexes (see below).
role in Tat transactivation. We recently found that HIV-1 We conclude that the direct binding of Tat to the cyclin
and HIV-2 Tat proteins bind with much higher affinity to T subunit of TAK/P-TEFb strongly influences both the
HIV-2 TAR (TAR-2) than to HIV-1 TAR (TAR-1) RNA in affinity and specificity of TAR RNA recognition.
vitro, despite the fact that both TARs function nearly If cyclin T is the TAR RNA-binding cofactor for Tat,
equivalently in transactivation, and that binding of free one prediction is that exogeneous synthetic wild-type
Tat to TAR-2 is significantly reduced by mutations in TAR decoy RNAs, as well as transdominant mutant Tat
proteins, should compete effectively for the formationthe duplicated loop sequences of TAR-2 RNA. Moreover,
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Figure 4. Analysis of the Binding of Tat,
Cyclin T, and Cyclin T±Tat Complexes to TAR
RNA in Gel Mobility Shift Experiments
(A) Binding of cyclin T and Tat-1 proteins to
TAR-1 RNA. Left panel: binding to wild-type
(odd-numbered lanes) or loop mutant (even-
numbered lanes) TAR-1 RNAs (11 to 180).
Where indicated, reactions contained 400 ng
of wild-type or activation domain mutant
GST-Tat-1 (aa 1±86) proteins and 750 ng of
GST±cyclin T. Right panel: analysis of binding
of Tat-1 and cyclin T to minimal (117 to 143)
TAR-1 RNAs. Where indicated, reactions
contained 125 ng GST-cleaved cyclin T and
100 ng GST-cleaved Tat-1 (aa 1±86). TAR-1
RNA probes (5 ng) were either wild-type
(lanes 17, 20, and 23), loop mutant (129/134,
substituting all six loop residues; lanes 18,
21, and 24), or bulge point mutant (U22A;
lanes 19, 22, and 25).
(B) Binding of cyclin T and Tat-2 proteins to
wild-type (odd-numbered lanes) or double
loop mutant (even-numbered lanes) TAR-2
RNA. Where indicated, reactions contained
400 ng of wild-type GST-Tat-2 (aa 1±99) or
400 ng of activation domain mutant GST-Tat-
2D8±47, and 750 ng of GST±cyclin T.
of the cyclin T±Tat:TAR ternary complex in vitro. As either purified Tat-1, cyclin T, or the cyclin T±Tat-1 com-
plex and subjected to partial digestion with differentshown in Figure 5A, binding of the cyclin T±Tat-1 com-
plex to TAR-1 RNA was effectively competed by an ribonucleases (RNase T1, cobra venom RNase, RNase
A). As shown in Figure 6A, binding of the cyclin T±Tat-1excess of wild-type TAR-1 or TAR-2 RNA and was not
inhibited by equivalent amounts of TAR loop mutant complex resulted in a specific protection of sequences
in the upper stem and loop of the TAR-1 RNA hairpinRNAs. The RNA-binding specificity of the cyclin T±Tat:
TAR complex correlates precisely with the ability of (cf. lanes 5, 9, and 13). No specific binding to TAR-1
RNA was observed with either cyclin T or Tat-1 alone.these TAR decoy RNAs to block Tat transactivation in
vitro (M. E. G., P. W., and K. A. J., unpublished data). In These data suggest that the cyclin greatly enhances the
stability and affinity of the Tat-1:TAR-1 interaction, andaddition, preincubation of the cyclin T protein with an
excess of the transdominant negative mutant Tat-1 (aa suggest that the binding of Tat-1 and cyclin T to TAR-1
RNA is cooperative. The binding of free Tat-2 protein to1±48) protein was sufficient to block the formation of
the cyclin T±Tat:TAR ternary complex (Figure 5B). By TAR-2 RNA resulted in the formation of a nuclease-
hypersensitive site at position G57 and a weak protec-contrast, the weak binding of free Tat to TAR-1 RNA
was not inhibited by GST-Tat-1 (aa 1±48) (compare lanes tion of sequences in the bulge and loop of the 59-hairpin
stem of TAR-2, whereas free cyclin T did not interact6 and 7 with lane 4), and comparable levels of the mutant
GST-Tat K41A (aa 1±48) protein did not interfere with with TAR-2 RNA. By contrast, the cyclin T±Tat-2 com-
plex bound avidly to sequences in the loop and stemthe formation of the cyclin T±Tat:TAR complex (compare
lanes 8 and 9 with lane 5). We conclude that the binding of both the 59- and 39-TAR-2 hairpin structures (Figure
6B, lanes 5, 9, and 13). The cyclin T±Tat-2 complexof the transdominant mutant Tat-1 (aa 1±48) protein to
cyclin T is sufficient to prevent formation of the ternary bound specifically to TAR under these conditions and
did not protect RNA sequences outside or between thecomplex with TAR RNA. The experiment shown in Figure
5B also demonstrates that the ARM of Tat is critical for two TAR-2 hairpin structures. Thus, cyclin T also en-
hances the affinity and stability of the Tat-2:TAR-2 inter-formation of the cyclin T±Tat:TAR complex, because the
transdominant GST-Tat-1 (aa 1±48) protein displayed no action in vitro.
affinity for TAR RNA, either alone or in the presence of
cyclin T (Figure 5B, lanes 2 and 3). Overexpression of Human Cyclin T Enhances
Tat Transactivation in Rodent
(NIH3T3, CHO) Cell LinesThe Cyclin T±Tat Complex Protects Sequences
in the Loop and Upper Stem of TAR RNA The observation that cyclin T is encoded on chromo-
some 12 and is required for high-affinity binding of Tatin RNase Footprint Experiments
The binding of the cyclin T±Tat complex to TAR RNA to TAR RNA raises the possibility that differences be-
tween the murine and human homologs of cyclin T maywas further assessed by RNase footprint protection ex-
periments. Radiolabeled TAR-1 RNA was incubated with be responsible for the partial defect in Tat activity that
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NIH3T3 and CHO (chinese hamster ovary) cell lines (Fig-
ure 7A). Basal HIV-1 transcription was unaffected by
cyclin T in these experiments, although a modest in-
crease inbasal expression was observed at higher levels
of cyclin T (data not shown), consistent with the pro-
posed general role of TAK/P-TEFb in transcription elon-
gation. These findings suggest that the human cyclin T
can act in combination with murine CDK9 to rescue Tat
activity in rodent cells. Overexpression of the human
CDK9 subunit had no significant effect on Tat transacti-
vation in these experiments (data not shown), indicating
that the kinase is not limiting for Tat activity in rodent
cells. These data suggest that cyclin T is limiting for Tat
transactivation in murine cells and may be responsible
for the previously-characterized species restriction to
Tat activity. Collectively, thedata presented in this paper
suggest that binding of Tat to the cyclin T subunit of
TAK/P-TEFb, as well as the subsequent cooperative
binding of the complex to TAR RNA, plays a central role
in transcriptional activation (Figure 7B). Details of this
model are discussed below.
Discussion
Tat Interacts Directly with a Nuclear Cyclin that
Is Associated with CDK9 in a Transcription
Elongation Complex
In the model shown in Figure 7B, Tat interacts through
its activation domain (AD) with the cyclin T subunit of a
preexisting TAK/P-TEFbcomplex. We speculate that the
interaction of Tat with cyclin T alters the conformation of
Tat to enhance greatly the affinity and specificity of the
Tat:TAR interaction. Although cyclin T has no affinity
for RNA on its own, it may nevertheless also provide
important contacts for TAR RNA when bound in the
complex together with Tat. Importantly, the in vitro RNA-
binding properties of the cyclin T±Tat:TAR complex cor-
relate precisely with the known sequence requirements
for TAR-dependent Tat transactivation. In particular, the
Figure 5. Analysis of the Specificity of the Cyclin T±Tat-1:TAR-1
formation of this complex requires both the activationComplex
domain and the ARM of Tat as well as the key sequences(A) Competition of the complex with wild-type and loop mutant TAR
in the loop and bulge of the TAR RNA hairpin. AlthoughRNAs. Where indicated, reactions contained 400 ng of GST-Tat-1
it has been suggested that the transcriptional coactiva-(aa 1±86), 750 ng of GST-cleaved cyclin T, and 5 ng labeled wild-
type TAR-1 RNA. Reactions either lacked competitor RNA (lanes tor for Tat would be distinct from its TAR RNA-binding
1±4), or contained competitor TAR RNA at a 100-fold (lanes 5, 8, cofactor, our results indicate that a single molecule
11, and 14), 200-fold (lanes 6, 9, 12, and 15) or 400-fold (lanes 7, (cyclin T) subserves both functions and that cyclin T
10, 13, and 16) molar excess to the radiolabeled RNA.
provides a direct link between Tat, TAR, and the TAK/(B) Analysis of the ability of GST-Tat-1 (1±48) to block the formation
P-TEFb elongation factor complex.of the cyclin T±Tat-1:TAR RNA complex. Reactions contained re-
The RNA-binding experiments shown here were car-combinant cyclin T and Tat proteins at the following levels: 750 ng
of GST±cyclin T (lanes 3 and 5±9), 400 ng of wild-type GST-Tat-1 ried out with Tat and free cyclin T, whereas cyclin T is
(aa 1±86) (lanes 4±9), 400 ng GST-Tat-1 (aa 1±48) (lane 6), 4 mg GST- normally bound to CDK9 in the cell (Figure 3). We have
Tat-1 (aa1±48) (lanes 2, 3, and 7), 400 ng GST-Tat-1 K41A (aa 1±48) recently found that Tat can also interact with a recombi-
(lane 8), or 4 mg GST-Tat-1 K41A (aa 1±48) (lane 9).
nant cyclin T±CDK9 complex and direct its specific bind-
ing to TAR RNA (M. E. G., P. W., and K. A. J., unpublished
data). However, CDK9 had no affect on the affinity orhas been characterized in murine (rodent) cell lines. To
assess this possibility, we carried out transient transfec- RNA-binding specificity of the complex beyond that re-
ported here for cyclin T alone, and CDK9 did not influ-tion experiments to examine the effect of overexpres-
sion of human cyclin T protein on Tat activity in rodent ence the binding of Tat to TAR in the absence of the
cyclin. Thus, the HIV-1 TAR RNA element appears tocell lines. Interestingly, overexpression of a form of the
human cyclin T protein lacking the C-terminal PEST se- have evolved to recognize Tat when bound to cyclin T
in the TAK/P-TEFb complex, rather than free Tat alone.quence (pCMV-HACycT) was found to enhance HIV-1
Tat transactivation by as much as 18-fold in murine Cooperative binding to TAR RNA might be an important
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Figure 6. RNase Footprint Analysis of the Binding of Cyclin T and Tat to HIV-1 TAR (TAR-1) AND HIV-2 TAR (TAR-2) RNAs
(A) RNase footprint protection analysis of the binding of cyclin T, Tat, and cyclin T±Tat complex to TAR-1 RNA. Where indicated, the 39 end-
labeled TAR-1 probe was incubated with 400 ng GST-Tat-1 (aa 1±86) and 750 ng GST-cleaved cyclin T. Reactions were treated with single-
strand specific RNase T1 (lanes 2±5), double-strand specific RNase CV (lanes 6±9), or single-strand specific RNase A (lanes 10±13). Brackets
highlight regions of RNase protection over the loop and upper stem of the TAR-1 stem-loop structure.
(B) RNase footprint analysis of the binding of GST-cleaved cyclin T and GST-Tat-2 (aa 1±99) proteins to TAR-2 RNA. Protein amounts were
the same as for (A).
mechanism to ensure that TAR molecules are bound and K. A. J., unpublished data), which suggests that the
free Tat protein may be configured poorly for bindingonly by Tat proteins that have previously associated
with cyclin T±CDK9 complexes in the cell. to RNA in the absence of cyclin T. Consequently, the
interaction of Tat with cyclin T may be necessary to alterIt is interesting to note that the activation domain of
Tat-1 (aa 1±48) functions as a potent dominant negative the structure of Tat for high-affinity binding to TAR RNA.
The cooperative binding of Tat and cyclin T to TAR RNAinhibitor of the wild-type Tat protein without affecting
basal HIV-1 transcription or general elongation, even provides a molecular explanation for the long-standing
observation that targeting and transactivation throughthough cyclin T and the TAK/P-TEFb complex are re-
quired for basal transcription from the HIV-1 promoter TAR RNA always requires the transactivation domain of
Tat, and that this region cannot be substituted by the(Figure 3C; Mancebo et al., 1997; Zhu et al., 1997). These
results suggest that Tat binds to a region of cyclin T activation domains of other transcription factors.
The TAR RNA recognition mechanism suggested herethat is not important for general transcription elongation
by the cyclin T±CDK9 complex. Thus, the region of the may resemble that proposed for other heteromeric RNA-
binding protein complexes. For example, it has beencyclin that is responsible for binding to Tat (and TAR)
may constitute an effective target for the development of shown that the mammalian U2 snRNP proteins, U2A9
and U2B99, must first interact with each other in ordernew inhibitory compounds that block Tat activitywithout
affecting the general transcription elongation properties to bind with high-affinity and specificity to U2 snRNA
(Scherly et al., 1990a, 1990b). Interestingly, neither pro-of the TAK/P-TEFb complex.
tein can recognize the specific U2 snRNA recognition
element on its own, although U2B99 binds RNA in aCyclin T as the TAR RNA-Binding Cofactor for Tat
Truncation of the N-terminal activation domain of Tat relatively nonspecific manner through its RNA recogni-
tion motif (RRM; Scherly et al., 1990a)and U2A9 interactsgreatly enhances its affinity for TAR RNA and reduces
the specificity of the Tat:TAR interaction (M. E. G., P. W., weakly with double-stranded RNA (Boelens et al., 1991).
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Figure 7. Overexpression of Human Cyclin T Enhances Tat Activity in Murine Cells
(A) Human cyclin T stimulates Tat transactivation in rodent cell lines. NIH3T3 and CHO cells were transfected with 100 ng pHIV-1/LUC, 10 ng
pSV-TatZX (2Tat), or pSV-Tat (1Tat), 10 ng of pRL-CMV (control plasmid), and different amounts of pCMV-HACycT, as indicated in the figure.
Shown are duplicate transfections from the same experiment. The firefly luciferase activity produced from pHIV-1/LUC was normalized to the
Renilla luciferase activity from the pRL-CMV plasmid (Promega). Cells were transfected with Lipofectamine (GIBCO-BRL) and luciferase activity
was measured 48 hr posttransfection.
(B) Biochemical view of the interaction of Tat with the cyclin T subunit of the CDK9-containing TAK/P-TEFb complex, and the subsequent
cooperative binding of Tat and TAK/P-TEFb to TAR RNA. See text for details.
Formation of the U2A9:U2B99 complex is thought to alter prior to transcription (Marshall and Price, 1992, 1995).
Tat may function to bypass the normal recruitmentthe conformation of U2B99 in a manner that greatly en-
hances its specific binding to the U2 snRNA element mechanism for TAK/P-TEFb by interacting directly with
cyclin T and promoting the association of the TAK/P-and also reduces its nonspecific binding to U1 snRNA.
Tat belongs to a different class of RNA-binding pro- TEFb complex with RNAPII. Thus, cooperative binding
of Tat-TAK/P-TEFb complex to TAR RNA might serveteins and interacts with RNA through an arginine-rich
motif (ARM), and its partner is a cyclin that lacks RNA to recruit the elongation factor to the HIV-1 promoter.
Because it has been reported that Tat can associaterecognition motifs and displays no intrinsic affinity for
RNA. Nevertheless, we envision that the interaction of with the RNAPII preinitiation complex (Garcia-Martinez
et al., 1997) or the RNAPII holoenzyme (Cujec et al.,Tat with cyclin T induces a conformational change in
Tat that significantly enhances its affinity and specificity 1997), it is possible that binding to TAR serves a different
function, for example to enhance CDK9 kinase activity orfor TAR-1 RNA, and may also inhibit the nonspecific
binding of Tat to the bulge region of loop mutant RNAs. alter the substrate specificity of the kinase. Biochemical
studies with immobilized DNA templates have shownThe ARM is essential for binding of the cyclin T±Tat
complex to TAR and provides important contacts within that Tat associates with elongating RNAPII only on tem-
plates that contain the wild-type TAR element, which isthe bulge of TAR RNA. It is possible that one or more
of the conserved aromatic residues in the hydrophobic consistent with a role for TAR in recruitment (Keen et
al., 1996, 1997). At later times in elongation, Tat bindscore of the transactivation domain of Tat might provide
important stacking interactions with bases in loop of to the RNAPII complex through protein:protein interac-
tions, and not through its ability to bind nascent TARthe TAR hairpin, as has been observed for other RNA-
binding proteins that recognize stem-loop structures RNA (Keen et al., 1997). Consequently, it will be impor-
tant to determine whether the cyclin T±CDK9 complex(Oubridge et al., 1994; for review, see Moras and Pot-
erszman, 1995). Finally, cyclin T may also directly con- associates with Tat in the RNAPII elongation complex,
or whether it acts only transiently through TAR RNA,tact TAR RNA within the complex (Figure 7B).
and whether TAK/P-TEFb plays any role in the transfer
of Tat from TAR to RNAPII.What Is the Role of TAR RNA?
The TAK/P-TEFb elongation factor complex is limiting Once recruited to the RNAPII transcription complex,
CDK9 may activate transcription through its demon-in extracts, and it has not been established how this
complex is recruited to promoters, although the Dro- strated ability to hyperphosphorylate the RNAPII CTD,
or it may function to phosphorylate other proteins thatsophila TAK/P-TEFb is not present in RNAPII complexes
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regulate elongation in a CTD-dependent manner. Re- onset of major zygotic gene activation during mamma-
lian development (Bellier et al., 1997).constituted transcriptionsystems support efficient elon-
gation of RNAPII transcription in the absence of TAK/
P-TEFb (Maldonado and Reinberg, 1995; Shilatifard et Species-Specific Regulation of Tat Activity
al., 1997), however transcription in such systems is not Interestingly, cyclin T fits several of the criteria that have
dependent upon the CTD and does not support Tat been established previously for the species-restricted
activation throughTAR (Mancebo et al., 1997). Reconsti- host cell cofactor for Tat (Hart et al., 1993; Alonso et al.,
tution of Tat activation in a reconstituted system was 1994). In particular, cyclin T confers upon Tat the ability
shown to require TAK/P-TEFb and a negative inhibitor to bind to TAR RNA in a loop-dependent manner and
(Mancebo et al., 1997), which suggests that TAK/P-TEFb is encoded on human chromosome 12. Moreover, we
may ultimately counteract a negative regulator of tran- find that overexpression of human cyclin T in NIH3T3
scription elongation. Tat activity is also likely to require and CHO cells significantly enhances Tat activity in vivo
other positively acting elongation factors (Zhou and (Figure 7A).The identification of proteins that can restore
Sharp, 1995, 1996). Tat function in rodent cells is an important goal for the
The role of the cyclin T±CDK9 complex in Tat-medi- development of transgenic mice that can be infected
ated transactivation is novel, although other transcrip- with HIV-1, which would provide a useful system tostudy
tion factors have been shown previously interact with the impact of viral infection on the immune system. In
cyclin±CDK complexes as direct substrates for phos- addition, it will be important to determine whether the
phorylation. In an interesting variation on this theme, it enhancement in Tat activation caused by overexpres-
was recently shown that a direct interaction between the sion of human cyclin T in rodent cells is sufficient to
human estrogen receptor (hER) and cyclin D1 enhances permit virus replication and to assess directly whether
binding of hER to DNA and induces ERE-dependent the murine cyclin T protein is defective in its ability to
transcription in the absence of ligand, thereby enabling interact with Tat or TAR RNA. Further studies character-
estrogen-independent growth of breast tumor cells that izing cyclin T should help to elaborate the mechanism
overexpress cyclin D1 (Zwijsen et al., 1997). of Tat transactivation and may also suggest new ap-
proaches to selectively block Tat activity in infected
cells.
Regulation of TAK/P-TEFb (CTD Kinase) Activity
Cyclin T is a novel human C-type cyclin, most closely Experimental Procedures
related to the essential S. pombe Pch1(1) cyclin, which
is a partner for CDC2-related proteins (Furnari et al., DNA Constructs
Plasmid pGST-Tat-1 K41A (aa 1±48) was subcloned into the BamHI1997). In yeast, the closest kinase to CDK9 is CTDK1,
and SmaI sites of pGEX-2T (Pharmacia), all other GST-Tat vectora CTD kinase that has been implicated in the control
constructs were obtained from Dr. A. P. Rice (Baylor Univ.). The full-of transcription elongation, although CTDK1 does not
length human cyclin T cDNA was subcloned into the NcoI and HindIII
mediate the DRB-sensitive step in transcription elonga- site of pGEX-KG to generate pGST-CycT. Exogenous TAR RNAs
tion in yeast extracts (Sterner et al., 1995; Lee and Green- for RNA-binding and invitro competition experiments were prepared
leaf, 1997). Other well-characterized cyclin C±related from plasmids pH96 WT and pH96 30/33 (11 to 180) (Sheline et al.,
1991). Plasmids pTAR2 WT and pTAR2 LM contain a single copyproteins are also nuclear and have been implicated in
of the wild-type or double loop mutant of TAR-2 RNA (11 to 1123),transcriptional control, including the cyclin H subunit of
respectively, and were subcloned into the HindIII and BamHI sitesTFIIH (Fisher and Morgan, 1994; Fisher et al., 1995) and
of pSP64 polyA vector (Promega). pCMV-HA-CycT encodes the
the yeast SRB10/11 cyclin-kinase pair associated with cyclin T gene lacking the PEST sequence (aa 1±708) as a XbaI-
RNAPII (Liao et al., 1995). Unlike other cyclins, which BamHI fragment in pCGN.
are differentially regulated throughout the cell cycle, the
levels of the C-type cyclins generally do not vary during Purification of p87 (CycT) from HeLa Nuclear Extract
Protein affinity selection with GST-Tat-1 (aa 1±48) and in vitro kinasecell division (Li et al., 1996). However, the C-type cyclins
assays were as described by Herrmann and Rice (1993), with acould represent important targets for environmental sig-
modified washing in buffer D (20 mM Tris-HCl [pH 8.0], 0.2 mMnaling pathways in the cell. For example, the UME3p
EDTA, 150 mM KCl, 0.5% NP-40, 0.05% SDS, 20% glycerol, 2 mM
(SRB11) cyclin, which has been implicated in transcrip- dithiothreitol, and 0.2 mM PMSF). These reactions were scaled up
tional repression of selected genes, is down-regulated 80-fold, and 1 mg (110 pmol) of human cyclin T protein was isolated
by proteolysis during heat shock (Cooper et al., 1997). on a preparative SDS-PAGE (6%), transferred to a PVDF membrane
(MSI), and stained with amido black. A detailed protocol is availableTat-associated CDK9 activity increases upon activation
from the authors upon request. HPLC-purified tryptic fragments ofof peripheral blood lymphocytes or differentiation of
p87 were subjected to peptide sequencing using the Perkin Elmerpromonocytic cell lines (Yang et al., 1997), which are
ABI 470 and Procise 494 systems.
conditions that induce viral transcription strongly. Con-
sequently it will be interesting to learn whether the levels Cloning of Cyclin T cDNA
of cyclin T protein or mRNA are increased upon T cell The I.M.A.G.E. Consortium Clone (ID 111460) containing an 0.9 kb
cDNA fragment of the gene (aa 236±481) encoding human cyclin Tactivation, and whether the interaction of Tat with cyclin
was obtained from the American Type Culture Collection. The cDNAT enhances the stability of the cyclin or TAK/P-TEFb
insert was sequenced on both strands and used to design primersactivity. Beyond these specific implications for Tat activ-
for 39 RACE PCR. The 0.8 kb 39 RACE PCR products (aa 482±726)ity, cyclin T could be regulated under the many varied
were subcloned in the EcoRI site of pGEM-7Z(f) and sequenced.
cellular conditions that have been shown to enhance The full-length cyclin T gene was obtained by screening one million
overall levels of RNAPII CTD hyperphosphorylation, in- phage from a lZAPII Jurkat cDNA library (Waterman et al., 1991)
using probes from the 0.9 kb cDNA and the 0.8 kb 39 RACE PCRcluding serum stimulation (Dubois et al., 1994) and the
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product. Probes for screening were labeled by random priming to RNase CV (0.035 U, Pharmacia), or RNase A (0.6 ng, Boehringer),
on ice for 15 min. Reactions were terminated with 85 ml of stopa specific activity of 1 3 109 dpm/mg. Positive plaques were purified
by rescreening, and the clone with the longest insert (7.2 kb) was buffer (100 mM Tris-HCl [pH 8.0], 1% Sarkosyl, 100 mM NaCl, 10
mM EDTA, and 25 mg/ml tRNA), prior to analysis on 12% denaturingsubjected to automatic DNA sequencing.
polyacrylamide gels.
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